Nanomedicine-RNAi interface: Architypes in prostate cancer therapeutics DOI

Saurabh Shah,

Paras Famta,

Dadi A. Srinivasarao

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 92, P. 105349 - 105349

Published: Jan. 6, 2024

Language: Английский

CD44 Methylation Levels in Androgen-Deprived Prostate Cancer: A Putative Epigenetic Modulator of Tumor Progression DOI Open Access
Virginia Valentini, Raffaella Santi, Valentina Silvestri

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2516 - 2516

Published: March 11, 2025

Epigenetic changes have been reported to promote the development and progression of prostate cancer (PCa). Compared normal tissue, tumor samples from patients treated with androgen-deprivation therapy (ADT) show hypermethylation genes primarily implicated in PCa progression. A series 90 radical prostatectomies was retrospectively analyzed. total 46 had undergone surgery alone (non-treated) 44 received ADT prior (treated). Promoter methylation analysis candidate possibly involved response (AR, ESR1, ESR2, APC, BCL2, CD44, CDH1, RASSF1, ZEB1) conducted by pyrosequencing. The mRNA expression differentially methylated investigated quantitative real-time PCR. Intratumoral microvessel density ERG were also assessed using immunohistochemistry. statistically significant difference CD44 promoter levels found, higher non-treated cases, which accordingly showed lower gene than cases. Moreover, ESR1 associated expression, increased ERG-overexpressing tumors, particularly Our data suggest an interplay between epigenetic modifications key tumorigenesis, that could serve as a promising molecular biomarker under androgen-deprived conditions.

Language: Английский

Citations

0
Photothermal treatment of prostate tumor with micellar indocyanine green and Napabucasin to co-ablate cancer cells and cancer stem cells DOI
Yun Qu, Beibei Guo, Songsong Zhao

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113704 - 113704

Published: April 1, 2025

Language: Английский

Citations

0
Polydatin inhibits the stemness and angiogenesis of gastric cancer cells by targeting down-regulation of HDAC7 DOI Creative Commons

Jialin Zhou,

Fucun Zheng,

Peng Dai

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: May 14, 2025

Language: Английский

Citations

0
Ferroptosis by nanomaterials: targeting cancer stem cells and overcoming drug resistance DOI Creative Commons
Xiaoman Wang,

Jing Luo,

Xuemei Zeng

et al.

Acta Materia Medica, Journal Year: 2025, Volume and Issue: 4(3)

Published: Jan. 1, 2025

Tumor ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as promising therapeutic strategy for combating cancers, particularly in cases involving cancer stem cells (CSCs) and drug resistance. In recent years nanomaterial-based approaches have gained significant attention the potential to selectively induce ferroptosis while sparing normal tissues. This review aims provide comprehensive overview current state-of-the-art utilizing nanomaterials targeting tumor with specific focus on application eradicating CSCs overcoming resistance mechanisms. The molecular mechanisms underlying induction nanomaterials, unique properties functionalities various nanomaterial platforms, strategies using nanoferroptosis will be discussed. addition, preclinical clinical evidence supporting efficacy platforms evaluated. Furthermore, challenges future perspectives development translation nanoferroptosis-based therapies precision treatment highlighted.

Language: Английский

Citations

0
Nanomedicine-RNAi interface: Architypes in prostate cancer therapeutics DOI

Saurabh Shah,

Paras Famta,

Dadi A. Srinivasarao

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 92, P. 105349 - 105349

Published: Jan. 6, 2024

Language: Английский

Citations

3